Microscopic Colitis & Medications: What to Know
- Many commonly prescribed medications may not substantially increase the risk of developing microscopic colitis, according to a recent study conducted in Sweden.
- previous reports suggested that nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs), statins, and antihypertensive agents could trigger microscopic colitis.
- The researchers analyzed extensive data from Swedish registries, including prescription records, hospitalizations, medical diagnoses, and gut biopsy results.
A groundbreaking Swedish study challenges previous beliefs regarding the link between medications and microscopic colitis. Researchers found that several common drugs, including nsaids, PPIs, statins, and antihypertensives, may not significantly elevate the risk of this primary_keyword condition. While SSRIs showed a slight increase in risk, the study suggests that the role of secondary_keyword medications in triggering microscopic colitis has been overstated. News Directory 3 delivers vital healthcare insights, and this report urges clinicians too reconsider medication benefits versus risks. The analysis, based on extensive data from Swedish registries, offers crucial new perspectives. Discover what’s next as the medical community continues to explore the disease.
Microscopic Colitis: Medication Risk Overstated, Swedish Study Finds
Updated July 2, 2025
Many commonly prescribed medications may not substantially increase the risk of developing microscopic colitis, according to a recent study conducted in Sweden. The research, involving more than 2.8 million adults aged 65 and older, examined the potential link between several drug classes and the growth of the condition.
previous reports suggested that nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs), statins, and antihypertensive agents could trigger microscopic colitis. However, the new study found little evidence to support this claim for most of these medications.
The researchers analyzed extensive data from Swedish registries, including prescription records, hospitalizations, medical diagnoses, and gut biopsy results. They emulated target trials for each medication, comparing the effect of initiating the drug versus not starting it or selecting an option.The primary outcome was biopsy-verified microscopic colitis.
The study revealed that the estimated risk differences at 12 and 24 months were minimal for initiating antihypertensive medications, NSAIDs, PPIs, and statins. However, the initiation of SSRIs compared to mirtazapine showed a slight increase in risk, with an estimated 0.04% difference at 12 months.
Interestingly, the use of nsaids, PPIs, and SSRIs was associated with more colonoscopy exams with normal biopsy results.this suggests that the apparent increase in microscopic colitis after starting an SSRI might be due to other factors influencing medical care.
“Our study demonstrated that,contrary to the previous belief,it’s unlikely that medications are the primary triggers for microscopic colitis,” said Hamed Khalili,MD,MPH,of Massachusetts General Hospital in Boston,who led the study.
Khalili and his colleagues published their findings in the journal Annals of Internal medicine. The study was funded in part by the National Institutes of Health,the Swedish Research Council,and the Eric and Wendy Schmidt Center at the Broad Institute of MIT and Harvard. Some authors disclosed financial ties to pharmaceutical companies.
What’s next
While the study provides reassurance about the safety of many common medications, clinicians should still carefully weigh the benefits and risks when prescribing these drugs, notably SSRIs, for older adults. Further research is needed to fully understand the factors that contribute to the development of microscopic colitis and the role of medications in its onset.